Montelukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is not useful for the treatment of acute asthma attacks, so patients should also be supplied with rescue medication, such as an albuterol inhaler. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1, thus inhibiting bronchoconstriction.
Montelukast is marketed by Merck & Co. with the brand name Singulair®. It is available as oral tablets, chewable tablets, and oral granules.

DrugDigest: Montelukast - Information on dosage, usage, side effects, interactions, and drug comparisons, including generics when available.
MedlinePlus- Montelukast - From the U.S. National Library of Medicine and National Institutes of Health. Includes information on the use of Montelukast, precations, and appropriate storage conditions.
Meta Description: [ Montelukast ]
Montelukast - National Asthma Council Australia - Describes this leukotriene receptor antagonist medication, including the indications, advantages and dosage.
Meta Description: [ The Asthma Management Handbook 2002 has been compiled by the National Asthma Council principally for
general practitioners, community pharmacists and asthma educators, but will be useful for all health professionals working in asthma care,
and for medical, pharmacy and nursing students. ]
Montelukast - UK Medicines Information - Information in PDF format, detailing efficacy, adverse effects, promotional data, and major clinical trial information. [Requires Adobe Acrobat Reader]
Singulair - Manufacturer's site. Includes possible side effects, prescribing information and proper usage instructions.
| FDA Studying Potential Safety Issues with Several Drugs | |
| Next Video | |